Gold prices slid below $4,000/oz amid profit-taking on Gaza ceasefire
Lilly Endowment Inc, a ten percent owner in Eli Lilly & Co (NYSE:LLY), has sold 85,810 shares of common stock on October 8, 2025. The sales, executed in multiple transactions, fetched a total of $86,234,873 with prices ranging from $848.46 to $856.0.
The transactions are detailed as follows: 18,132 shares were sold at an average price of $848.46; 25,296 shares at an average of $849.597; 36,114 shares at an average of $850.519; 13,624 shares at an average of $851.403; 3,227 shares at an average of $852.361; 3,881 shares at an average of $853.846; 946 shares at an average price of $854.639 and 200 shares at $856.
Following these transactions, Lilly Endowment Inc. directly owns 94,547,580 shares of Eli Lilly & Co.
In other recent news, Eli Lilly is preparing to release its third-quarter earnings report, with Guggenheim projecting Mounjaro sales to reach $5.49 billion, slightly surpassing the consensus estimate of $5.43 billion. The firm’s forecast for U.S. sales is $3.50 billion, compared to the consensus expectation of $3.46 billion. Additionally, Eli Lilly announced that its ulcerative colitis treatment, Omvoh, has shown sustained efficacy over four years, with 80% of patients maintaining long-term clinical remission and 93% experiencing significant improvement in bowel urgency. Guggenheim has raised its price target for Eli Lilly to $948, maintaining a Buy rating, highlighting the strength of tirzepatide. TD Cowen also reiterated a Buy rating, keeping its price target at $960, citing the company’s excellent growth prospects and consistent innovation. Furthermore, Guggenheim continues to support Eli Lilly with a Buy rating and a maintained price target of $875, noting strong growth projections for 2025. These developments reflect ongoing investor interest in Eli Lilly’s innovative treatments and growth potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.